This is a new era of non-toxic personalized medicine for cancer. We are targeting cancer stem cells (the seeds of cancer) and the molecular signaling pathways that allow for tumor regrowth and spread for the first time since cancer was discovered. Targeting cancer stem cells and their embryonic signaling pathways without toxicity is crucial. We continue to pursue these targets across multiple cancer types as a strategy for reversing tumor growth. In addition, with the renaissance of immunotherapy, we have solved the complex interplay with the tumor immune microenvironment and the immune system. Our new therapies will play an important role in enhancing the tumoricidal capabilities of new immune therapies in solid tumors.